C-type lectin domain family 18 member AGenealiases: MRCL · MRCL1 · MRLP2
Q-omics provides the consensus-scored CLEC18A profile across patient tissues and cancer cell-line models. CLEC18A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLEC18A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CLEC18A RNA expression shows 8,637 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where CLEC18A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC18A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC18A survival associations across molecular data types. CLEC18A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC18A RNA expression–survival associations across cancer types. High CLEC18A expression shows unfavorable associations in COAD, LGG and LIHC, but favorable associations in KIRC, LUAD and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLEC18A RNA expression.
This table summarizes CLEC18A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLEC18A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC18A shows lower tumor expression in KICH and KIRP and higher tumor expression in KIRC, HNSC, LIHC and BLCA. The KIRC box plot shows higher CLEC18A RNA expression in tumor versus normal tissue (log2 FC = +2.437, t-test p < 0.001).
This table shows molecular features associated with CLEC18A in patient tissues and cancer cell lines. In patient samples, CLEC18A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC18A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
